JHPCY — Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 2071868 ·
China
Last close
$13.60
Market Cap
$1.76B
52W High
$18.00
52W Low
$13.60
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,140,565,321 | 7,049,616,182 | 2,579,989,309 | 2,282,268,233 | 71,293,862,441 | 40,526,883,023 | 7,146,776,163 |
| Dec 2025 | 8,441,334,265 | 7,274,119,633 | 2,330,380,135 | 1,959,885,274 | 69,867,315,774 | 40,955,482,468 | 8,070,492,359 |
| Jun 2025 | 8,555,582,506 | 7,509,282,853 | 2,807,885,640 | 2,576,050,864 | 62,893,517,149 | 36,121,847,259 | 3,863,719,109 |
| Mar 2025 | 7,205,611,123 | 6,136,948,606 | 2,018,181,174 | 1,874,055,520 | 51,292,781,691 | 24,085,707,596 | 3,743,012,633 |
Balance + Analyst (yfinance extras)
Retained Earnings
$42,455,623,061
Inventory
$2,886,056,361
Receivables
—
ST Investments
$108,916,478
EBIT TTM
$9,917,521,709
Pretax Income TTM
$9,903,414,008
Interest Exp TTM
$14,107,702
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$32,564,369,408
EBITDA
$9,452,852,224
Free Cash Flow
$6,307,738,624
Enterprise Value
$22,513,496,064
Total Cash
$40,635,797,504
Total Debt
$67,474,744
Shares Out
129,098,800
Trailing EPS
$0.36
Book Value
$2.81
ROE
14.5%
ROA
8.8%
Div Yield
0.43%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 31,629,416,194 | 8,596,411,752 | 7,711,054,812 | 69,867,315,774 | 8,070,492,359 | — | 11,235,378,131 |
| Dec 2024 | 27,984,605,342 | 6,803,132,569 | 6,336,527,015 | 50,135,645,304 | 4,045,394,571 | — | 7,422,753,039 |
| Dec 2023 | 22,819,784,741 | 4,625,728,312 | 4,302,435,930 | 43,784,506,636 | 2,751,420,194 | — | 7,643,665,075 |
| Dec 2022 | 21,275,270,682 | 3,344,720,696 | 3,906,375,067 | 42,370,875,898 | 3,957,967,303 | — | 1,265,264,632 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BDJ | BlackRock Enhanced Equity Dividend Trust | $1.75B | $9.89 | — |
| CPRI | Capri Holdings Ltd | $1.77B | $15.55 | — |
| GDV-PH | GABELLI DIVIDEND & INCOME TRUST | $1.74B | $21.16 | — |
| ETV | Eaton Vance Tax-Managed Buy-Write Opportunities Fund | $1.77B | $15.14 | — |
| AVVSY | Avio S.p.A./ADR | $1.77B | $9.60 | — |
News headlines (Yahoo Finance, 1h cache)
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
2026-06-30 05:00 · Yahoo
Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion
2025-10-27 11:34 · Yahoo
Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
2025-09-24 11:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.